Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | APOB | P04114 | 6/20 | 0.52 |
| ▸ | MTTP | P55157 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KLRK1 | P26718 | 3/20 | 0.49 |
| ▸ | MICA | Q29983 | 3/20 | 0.49 |
| ▸ | RAET1L | Q5VY80 | 3/20 | 0.49 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480249 | 0.84 | TRPV1 (0.53) | TRPV1SMN1; SMN2SLC6A4SLC6A3 | |
| Xenalipin SCHEMBL29881739 | 0.84 | CYP2C8 (0.58) | BACE1APOBMTTPGAAKLRK1 | |
| Xenalipin SCHEMBL133087 | 0.84 | CYP2C8 (0.58) | BACE1APOBMTTPGAAKLRK1 | |
| SCHEMBL403609 | 0.83 | GAA (0.51) | BACE1APOBMTTPGAAKLRK1 | |
| SCHEMBL2564888 | 0.83 | BCAT2 (0.65) | BACE1GAAKLRK1MICARAET1L | |
| SCHEMBL171527 | 0.83 | KIF11 (0.47) | TRPV1BACE1APOBMTTPGAA | |
| Xenalipin SCHEMBL3723586 | 0.83 | CYP2C8 (0.56) | BACE1APOBMTTPGAAKLRK1 | |
| SCHEMBL6799567 | 0.82 | APOB (0.61) | TRPV1APOBMTTPPTGS1SMN1; SMN2 | |
| SCHEMBL6850836 | 0.82 | GAA (0.61) | APOBMTTPGAAKLRK1MICA | |
| SCHEMBL10645473 | 0.82 | SLC6A3 (0.69) | BACE1APOBMTTPGAAKLRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021094436-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| US-9273080-B2 | Metal complexes | MEREK PATENT GMBH (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20130082209-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2013-04-04 | — | — | US | disclosed |
| EP-1694644-B1 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTEIN B | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130082209-A1 | METAL COMPLEXES | MCOLN2, MCOLN1, AP1M1 | TRPV1 2188/4885BACE1 1595/4885APOB 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.